Selective cleavage of primary MPM ethers with TMSI/Et3N
摘要:
A useful method for the selective cleavage of primary MPM ethers by using TMSI/Et3N is described. Other protective groups such as secondary MPM ethers, silyl ethers, and benzylidene acetal were stable under the reaction conditions. (C) 2009 Elsevier Ltd. Ail rights reserved.
Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
申请人:Unoki Gen
公开号:US20070173519A1
公开(公告)日:2007-07-26
A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.
A Unified and Practical Method for Carbon–Heteroatom Cross‐Coupling using Nickel/Photo Dual Catalysis
作者:Randolph A. Escobar、Jeffrey W. Johannes
DOI:10.1002/chem.202000052
日期:2020.4.21
While carbon-heteroatom cross-couplingreactions have been extensively studied, many methods are specific and limited to a particular set of substrates or functional groups. Reported here is a general method that allows for C-O, C-N and C-Scross-couplingreactions under one general set of conditions. We propose that an energy transfer pathway, in which an iridium photosensitizer produces an excited
Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof
申请人:UNOKI Gen
公开号:US20090054472A1
公开(公告)日:2009-02-26
A pyrazolopyrimidine derivative represented by formula (1) and pharmaceutically acceptable salt thereof exhibit excellent inhibitory activity against MAPKAP-K2. Accordingly, medicines containing this compound as an active ingredient are expected to be effective for treating diseases mediated by MAPKAP-K2 such as, for example, inflammatory disorder, autoimmune diseases, destructive osteopathy, cancer and/or tumor growth.
UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
申请人:Chao Hannguang J.
公开号:US20080280905A1
公开(公告)日:2008-11-13
The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y
1
receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y
1
receptor activity.
One-pot migration–formylation of benzyl aryl ethers under Duff reaction condition
作者:Subhash P. Chavan、Pradeep B. Lasonkar
DOI:10.1016/j.tetlet.2013.06.133
日期:2013.8
A one-pot migration-formylation of benzyl aryl ethers under Duff reaction condition is described. The reaction was performed with HMTA (hexamethylene tetramine) and TFA (trifluoroacetic acid). Under the optimal reaction conditions, a variety of Bn and PMB ethers underwent ortho rearrangement. (C) 2013 Elsevier Ltd. All rights reserved.